Melanotan II is one of those peptides everyone jokes about until they actually run it… and suddenly the meme makes sense.
You go outside for 10 minutes, come back looking like you spent a week in Ibiza.
And people still pretend this is “just a tanning peptide.”
It’s not.
It’s literally a melanocortin receptor agonist with systemic side effects some useful, some not, some hilarious.

But you need to understand the underlying biology or you’re going to get blindsided by the real effects.

Interest in Melanotan II across the UK, Europe, and broader EU peptide communities has surged in recent years, particularly among users in countries where tanning culture and sun exposure are central to lifestyle. But most people are running it wrong.

What MT2 is actually doing

Let’s break it down in a way that isn’t bro-science:

Melanotan II is a synthetic analog of α-MSH (alpha-melanocyte stimulating hormone).
That means it’s hitting MC1R the receptor responsible for melanin production but it’s also hitting MC3R, MC4R, and MC5R to varying degrees.

And that’s where the side effects come from.

MC1R → melanin → darker skin
MC3R → appetite modulation
MC4R → libido/erectile function
MC5R → sebaceous glands, sweating, secondary effects

People act surprised when they get random libido spikes or appetite suppression.
It’s not magic.
It’s literally built into the receptor profile.

This is why some guys tan insanely fast genetics.

Why you tan so fast

Most people underestimate how much melanin synthesis MT2 amplifies.

When you pin MT2, you’re basically telling your melanocytes:

“Go. All of you. Right now.”

So even minimal UV exposure like walking outside triggers disproportionately high melanin output.
This is why:

– you tan faster
– your tan gets darker
– you hold color longer
– and you burn significantly less

This isn’t bronzer.
This is literally altering how your melanocytes respond to UV radiation.

For users across the UK and Northern Europe where natural sun exposure is limited, this makes MT2 particularly effective at achieving a deep, lasting tan even from brief tanning bed sessions or the occasional sunny day.

What it feels like

People underestimate the subjective experience:

Day 1–3:
Transient nausea, slight flushing. Classic MT2 response.
If you dose too aggressively out of the gate, you will absolutely feel it.

Week 1:
You start picking up color from incidental sunlight.
You’ll look down at your arms and see that “holy sh*t” moment.

Week 2–3:
The tan becomes noticeable to everyone else.
UV sessions (sun or tanning bed) become absurdly efficient.
Your skin tone gets deeper and more uniform.

Week 4+:
You hit that “Mediterranean for no reason” look.
Color retention goes way up melanin stays elevated even without continuous exposure.

This is the effect that makes MT2 so popular in the UK and across Northern and Central Europe, where achieving and maintaining a deep tan through natural sun alone is simply not realistic for most of the year.

Libido effects

Everyone pretends they don’t want to talk about this, but let’s just be adults.

Melanotan II hits MC4R hard enough that erectile function goes up in many users.
This is the same receptor targeted in pharmaceutical libido drugs being tested right now.

So yes, MT2 increases libido in many people.
No, it’s not “in your head.”
Yes, this is normal.
No, it doesn’t mean something is wrong with you.

Side effects

The commonly reported ones:

– nausea (dose-dependent)
– flushing
– darkening of existing moles/freckles
– increased libido
– appetite suppression

The mole darkening is the one people ignore.
If you have atypical nevi, family history, or any suspicious lesions, don’t run MT2.
This isn’t fearmongering overstimulating melanocytes is not something you want to do if you're already at risk.

Safety

This needs to be stated clearly:

Melanotan II is not FDA-approved, and it holds no EMA or MHRA approval for human use in the EU or UK. There is no long-term human data on chronic usage. Peptide quality between research suppliers varies considerably, particularly across European vendors where regulatory oversight differs by country.

If you’re going to run it, understand what system you’re messing with.

Dosing

Loading Phase Weeks 1–2

• Days 1–3 → 0.25mg daily

• Days 4–7 → 0.5mg daily

• Week 2 → 0.5–1mg daily

(Build base melanin / faster tanning response)

Tanning Phase Weeks 3–6

• 0.5–1mg on tanning days

• Dose 30–60 minutes before UV exposure

• 2–4 tanning sessions per week

(Adjust based on skin type / darkness response)

Maintenance Phase Weeks 7–12

• 0.25–0.5mg 2–3× weekly

• Maintain desired color

• No daily dosing needed

Reconstitution

10 mg vial
Add 2 mL BAC → 5 mg/mL

1 mg = 0.2 mL
0.5 mg = 0.1 mL

Why people actually run MT2

It's not just tanning. It's:

• photoprotection
• cosmetic enhancement
• confidence going into summer
• holiday and vacation prep
• bodybuilding stage prep
• libido benefits
• meaningfully reduced burn risk

It fundamentally changes your relationship with UV exposure. For users in the UK and across Europe where sun is a seasonal luxury, that shift is especially significant.

Community

If you've run MT2 in the UK or Europe, share what your response profile actually looked like. European user data is particularly useful here given the differences in skin types, UV availability, and tanning bed culture across the continent:

– How fast did your tan actually develop?
– Did you get the nausea?
– Did libido spike or stay baseline?
– Did your moles darken?
– Did you respond better to sun or tanning beds?

Drop it below.

Tesamorelin is one of those peptides that gets tossed around in conversations like it's some kind of magic "fat-loss injection," when in reality it's a very specific, highly targeted growth-hormone-releasing analog that does one thing exceptionally well: elevate GH and IGF-1 through a clean, predictable GHRH pathway.

Interest in Tesamorelin across the UK, Europe, and the broader EU peptide community has grown significantly over the past few years, and for good reason. But the problem is people approach it like a shortcut. It isn't. It's a precision tool. And to use it correctly, you need to understand what it actually does, and more importantly, what it doesn't do.

Let's break it down.

Mechanistically -- What Tesamorelin Actually Does

Tesamorelin is a stabilized GHRH analog. Meaning: it closely mimics the exact hormone your hypothalamus uses to signal your pituitary: "Release more growth hormone."

But unlike natural GHRH, which gets broken down faster than your willpower on a cut, Tesamorelin is structurally modified to survive long enough to produce a GH spike in a far more reliable, sustained way.

The key points:

• Increases pulsatile growth hormone secretion. You're amplifying the body's natural pulses, not suppressing them with the constant GH elevation that exogenous HGH produces
• Raises IGF-1 significantly, typically in the same range as 1 to 2 IU of pharmaceutical GH
• Enhances lipolysis and drives visceral fat reduction, which is the part everyone fixates on
• Carries a relatively clean receptor profile with no artificial GH spillover and no off-target activity

If your goal is to support the physiologic pattern of GH rather than override it entirely, Tesamorelin makes more sense than exogenous growth hormone for the majority of people. This holds true whether you're running it in the UK, Germany, the Netherlands, Scandinavia, or anywhere else in Europe where access to quality research peptides has expanded considerably in recent years.

Why It Works So Well for Fat Loss, Specifically Visceral Fat

This is the part most people consistently misunderstand, and it comes up constantly in European and UK peptide communities.

Tesamorelin wasn’t designed as a bodybuilding drug.
It was FDA-approved to reduce excess visceral adipose tissue (VAT) in HIV patients with metabolic disturbances.

And it turns out… the mechanism they were targeting applies to everyone:

GH → increases lipolysis → preferentially mobilizes visceral fat first.

Subcutaneous fat loss still improves, but VAT is the big mover.
If you’ve ever wondered why some guys look like they’re lean on the outside but still have that “GH gut” appearance — that’s visceral fat.

Tesamorelin helps reverse that.

It doesn’t magically chisel you if you’re eating garbage.
But if your diet is dialed in, Tesamorelin gives you a noticeably tighter midsection, improved insulin sensitivity, and better nutrient partitioning.

These outcomes have been consistently reported by users across UK, German, French, and broader Europe fitness communities running it as a standalone research peptide.

What It Feels Like in Real Life

The subjective effects are pretty consistent:

Week 1:
Sleep quality bumps up a bit.
You feel warmer at night.
Some guys report mild water retention, nothing crazy.

Week 2–3:
You notice subtle changes in midsection tightness.
Recovery gets slightly better.
Pumps improve.

Week 4–8:
This is where people start seeing the visceral fat reduction.
Your waist just looks smaller even if scale weight hasn’t changed.
IGF-1 is typically sitting in the upper-normal to supraphysiological range.

No, you’re not suddenly blasting GH like a 1990s bodybuilder.
But the “I just look healthier and tighter” effect is very real.

Dosing

The clinically validated dose:

2 mg subcutaneous once daily

Yes, 2 mg.
Not 500 mcg.
Not 1 mg.
Tesamorelin has been studied extensively — 2 mg is where you get the meaningful bump in IGF-1 and visceral fat reduction.

Some people do run it at 1-1.5mg though if cost is a concern and still are able to get some good results out of it.

Timing:
Most people pin it before bed, but physiologically it doesn’t matter that much because it amplifies your normal GH pulses.
Pre-sleep is just convenient.

Side Effects

The ones you'll actually encounter:

• Edema and water retention
• Mild tingling or numbness
• Transient insulin resistance (rare, but worth knowing)
• Increased appetite driven by IGF-1
• Vivid dreams
• Mild fatigue in the first week

Notice what's absent from that list: No prolactin elevation. No estrogen complications. No thyroid suppression. None of the predictable fallout that comes with exogenous GH overdosing.

Tesamorelin has a surprisingly favorable tolerability profile, which is a large part of why it has become one of the most discussed GHRH analogs across UK and EU peptide research communities in recent years.

Risks and Safety

Here's the honest assessment:

Tesamorelin holds FDA approval but only in its pharmaceutical form (Egrifta). In the EU and UK, it carries no EMA or MHRA approval for clinical use, meaning it is available strictly as a research peptide and should be treated accordingly. Regulations vary by country across Europe, so always verify the legal status in your specific jurisdiction before purchasing.

That said, the mechanism is well-characterized, the half-life is predictable, and the long-term safety data on therapeutic dosing is substantially stronger than most compounds people inject without a second thought.

On the topic of cancer risk, here's the nuance worth understanding: Growth hormone doesn't cause cancer. But elevated IGF-1 can accelerate the proliferation of already-existing cancer cells.

If you have a known malignancy or any suspicious lesion, this is not a compound you should be touching.

Reconstitution

Tesamorelin typically comes in a 10 mg vial. Reconstitute with 2 mL of BAC water. 10 mg divided by 2 mL = 5 mg per mL Your working concentration is 5 mg/mL.

To hit the 2 mg clinical dose: 2 mg divided by 5 mg/mL = 0.4 mL

On a standard 100-unit insulin syringe: 0.4 mL = 40 units

Practical Takeaways

• Tesamorelin is one of the cleanest GH secretagogues available
• It reliably raises IGF-1 without disrupting natural pulsatility
• It preferentially targets visceral fat, a genuinely rare quality in fat-loss agents
• Sleep quality, recovery, and general sense of wellbeing tend to improve
• The side effect burden is mild relative to exogenous GH
• It has become one of the more widely trusted GHRH analogs within UK and European peptide research communities

It isn't a miracle. It isn't a shortcut. But it is one of the rare compounds where the mechanism and the real-world outcomes actually align.

Community

If you've run Tesamorelin in the UK or Europe, share the real data.

• How long before your waist measurement shifted?
• Did you experience appetite swings from the IGF-1 increase?
• Did you compare the results directly to exogenous HGH?
• Any issues with numbness or water retention?
• Did sleep quality improve or was the effect negligible for you?
• How did you approach dosing, strictly 2 mg or did you experiment?
• Did visceral fat reduction actually show up in your physique?

Good or bad side effects. Not just nausea or water retention.

Could be better sleep, anxiety disappearing, insane hunger, zero appetite, panic attacks, crazy dreams, skin changes, libido spikes, emotional numbness, feeling “off,” etc.

What compound caused it ?

WHAT IS IT?

The Semax / Selank / Dihexa Nasal Spray is a triple-compound nootropic formulation delivering 5mg of each peptide per bottle in a single intranasal solution. It combines the dopaminergic activation and BDNF upregulation of Semax, the anxiolytic and stress-buffering properties of Selank, and the uniquely potent synaptic growth and memory enhancement of Dihexa into one convenient delivery system. The result is a comprehensive cognitive enhancement stack that addresses focus, anxiety, memory formation, and neuroprotection simultaneously through three distinct and complementary neurological mechanisms.

WHO IS IT FOR?

Ideal candidates:

• Individuals seeking a comprehensive, multi-pathway cognitive enhancement protocol in a single convenient format
• Those who want the combined benefits of Semax and Selank alongside the more potent and longer-acting synaptic enhancement of Dihexa
• People experiencing cognitive decline, memory impairment, or age-related reductions in processing speed and learning capacity
• High-performing individuals in cognitively demanding roles who want a foundational nootropic stack without managing multiple separate compounds
• Those recovering from traumatic brain injury, stroke, or neurological events where BDNF, synaptic growth, and neuroprotection are all priorities
• Biohackers and longevity-focused individuals wanting the most comprehensive nootropic peptide coverage available in a single preparation

Not recommended for:

• Pregnancy or breastfeeding
• Individuals with a history of psychosis, schizophrenia, or significant dopaminergic dysregulation without medical supervision
• Those on MAOIs, benzodiazepines, SSRIs, or SNRIs without medical oversight given the overlapping neurotransmitter activity of all three compounds
• Individuals with active seizure disorders
• People sensitive to stimulant-adjacent effects; the dopaminergic activity of Semax within the blend can produce overstimulation in sensitive users
• Those new to nootropic peptides who have not assessed individual compound tolerance separately; the combination amplifies effects and makes isolating the source of any adverse reaction more difficult

PRIMARY USE CASE

The primary use case for this formulation is comprehensive cognitive enhancement through simultaneous activation of three distinct neurological pathways. Rather than targeting a single mechanism, the combination addresses the full cognitive performance stack including focus and drive (Semax), emotional stability and stress resilience (Selank), and deep synaptic remodeling and memory enhancement (Dihexa) in a single administration.

Dihexa, the third and least commonly known compound in this blend, deserves particular attention. It is a small molecule derived from angiotensin IV that has demonstrated the ability to potently upregulate hepatocyte growth factor (HGF) and its receptor c-Met, which together drive synaptogenesis, the formation of new synaptic connections between neurons. In preclinical research, Dihexa was reported to be approximately ten million times more potent than BDNF in driving synaptogenesis, making it one of the most powerful known promoters of new synaptic growth and one of the most compelling compounds for cognitive restoration and enhancement.

Secondary benefits of the combined formulation include neuroprotection across multiple pathways, reduced neuroinflammation, improved mood and emotional regulation, enhanced learning and memory consolidation, stress resilience, and immunomodulation from Selank's tuftsin-derived activity.

MECHANISM OF ACTION

Each compound in the formulation contributes a distinct and complementary neurological mechanism:

Semax: Dopaminergic Activation and BDNF Upregulation Semax stimulates BDNF and NGF expression in the hippocampus and prefrontal cortex while modulating dopaminergic and serotonergic tone. This produces enhanced focus, motivation, working memory, processing speed, and neuroplasticity. It is the activating and drive-enhancing component of the formulation.

Selank: GABAergic Modulation and Anxiolytic Balance Selank modulates GABAergic tone, slows enkephalin degradation, and upregulates BDNF through a pathway partially distinct from Semax. It provides anxiolytic balance to Semax's dopaminergic activation, preventing overstimulation while adding emotional stability, stress resilience, and immunomodulatory support. It is the calming and balancing component of the formulation.

Dihexa: Synaptogenesis and Synaptic Remodeling Dihexa upregulates hepatocyte growth factor (HGF) and activates its receptor c-Met in brain tissue, driving the formation of new dendritic spines and synaptic connections between neurons. This synaptogenic activity operates at a deeper structural level than BDNF-driven neuroplasticity alone, potentially producing lasting improvements in cognitive architecture rather than purely functional enhancements. It is the deep structural and memory-remodeling component of the formulation.

The Combined Effect The three mechanisms are complementary and largely non-redundant. Semax and Selank both upregulate BDNF through overlapping pathways, producing additive neurotrophic support, while Dihexa's HGF and c-Met-driven synaptogenesis adds a structurally distinct layer of synaptic growth on top. The dopaminergic activation of Semax and the GABAergic balancing of Selank work in opposition to each other in a productive way, producing a state of calm, focused alertness that neither compound achieves as cleanly alone.

DOSING PROTOCOL

Each bottle contains 5mg of Semax, 5mg of Selank, and 5mg of Dihexa in a single intranasal solution. Dosing is administered via nasal spray with each spray delivering a fixed volume of the combined solution.

• Route: Intranasal
• Frequency: Once or twice daily
• Timing: Morning dosing is recommended for most users. A second dose in early afternoon is appropriate for extended cognitive demand but evening dosing should be avoided given Semax's dopaminergic activity and potential for sleep disruption.

Standard dosing:

• Starting dose: 1 spray per nostril once daily (approximately 100mcg of each compound per full dose depending on spray volume)
• Moderate dose: 1 to 2 sprays per nostril once daily
• Higher dose: 2 sprays per nostril twice daily for experienced users with established tolerance

Because Dihexa is significantly more potent per microgram than Semax or Selank, start conservatively and assess cognitive and mood response before increasing dose. Dihexa's effects are longer-lasting than the other two compounds and can accumulate with repeated dosing.

Cycle guidance:

• Standard cycle: Not necessary
• Given Dihexa's potency and longer duration of action, some practitioners recommend shorter cycles of 2 weeks on and 2 weeks off for this combination

WHAT TO EXPECT: TIMELINE

Days 1 to 3: Effects from Semax and Selank are typically noticeable within the first one to two doses. Improved mental clarity, reduced anxiety, enhanced focus, and a calm, alert cognitive state are among the earliest reported effects. Dihexa's synaptogenic effects operate on a longer timeline and are not acutely perceptible in the way that neurotransmitter modulation is.

Days 3 to 7: The Semax and Selank components produce consistent cognitive enhancement and emotional stability. Some users begin noticing improvements in memory recall and information retention by the end of the first week as the early synaptogenic effects of Dihexa begin to contribute alongside the neurotrophic effects of the other two compounds.

Weeks 2 to 4: BDNF upregulation from both Semax and Selank produces cumulative neuroplasticity benefits. Dihexa's synaptogenic activity becomes increasingly apparent in enhanced memory consolidation, learning speed, and associative thinking. Many users report that this is where the formulation feels qualitatively different from Semax and Selank alone, with a deeper and more structural quality to the cognitive improvements.

Weeks 4 to 8: Full cumulative benefits of all three compounds are most evident. Memory, learning, focus, emotional regulation, and cognitive resilience are all improved simultaneously. Users engaged in intensive learning or skill acquisition during this window often report the most significant subjective results given the combination of enhanced encoding (Dihexa synaptogenesis) and improved retrieval and processing (Semax and Selank neurotransmitter modulation).

STACK COMPATIBILITY

Pairs well with:

• MOTS-c for foundational mitochondrial and cellular energy support in neurons alongside central cognitive enhancement
• BPC-157 for gut-brain axis support, systemic anti-inflammatory effects, and dopaminergic system support that complements Semax's mechanism
• Lion's Mane mushroom extract for additional NGF support layered on top of the formulation's BDNF activity
• Low-dose Methylene Blue for mitochondrial electron transport chain support in neurons enhancing the energy substrate available for the synaptic remodeling Dihexa drives
• Omega-3 fatty acids (DHA in particular) to support neuronal membrane integrity and synaptic function alongside Dihexa's synaptogenic activity

Use with caution:

• SSRIs, SNRIs, MAOIs, and other serotonin or dopamine modulating medications given Semax's neurotransmitter activity
• Benzodiazepines and GABAergic medications given Selank's GABAergic modulation
• Racetams and other synaptogenic or cholinergic nootropics given Dihexa's potent synaptogenic activity; additive cognitive stimulation can produce overstimulation in sensitive individuals
• Stimulants including high-dose caffeine given Semax's dopaminergic component

Avoid:

• Evening dosing given Semax's potential for sleep disruption
• Exceeding recommended doses given the potency of Dihexa and the limited human safety data available for all three compounds in combination
• Use without an established tolerance to each compound individually for first-time users if possible; starting with the combination without prior individual compound experience makes adverse reaction assessment more difficult

SIDE EFFECTS

The side effect profile reflects the combined activity of all three compounds. Most adverse effects are mild, dose-dependent, and consistent with the individual compound profiles.

• Mild stimulation or restlessness: driven primarily by Semax's dopaminergic activity; managed by dose reduction or avoiding afternoon dosing
• Mild sedation or cognitive softening: occasionally reported, more likely if Selank's GABAergic effects predominate at the individual level; typically resolves with dose adjustment
• Nasal irritation: the most common practical complaint with intranasal administration of any multi-compound solution; rotating nostrils and allowing 30 to 60 seconds between nostrils minimizes this
• Headache: occasionally reported, typically mild and early in the cycle
• Sleep disruption: possible with afternoon or evening dosing due to Semax's dopaminergic activity; morning dosing mitigates this effectively
• Appetite changes: mild changes in either direction reported by some users
• Overstimulation at higher doses: the combined dopaminergic and synaptogenic activity can produce anxiety, mental racing, or heightened arousal in sensitive individuals; dose reduction resolves this
• Brief adjustment period after cessation: some users report a short window of reduced cognitive sharpness or mild mood changes as neurotransmitter systems normalize; typically mild and brief

Given Dihexa's exceptional potency and limited human safety data, the overall uncertainty profile of this combination is higher than for Semax and Selank alone. Caution, conservative dosing, and medical oversight are particularly important with this formulation.

STORAGE AND HANDLING

• Prepared nasal solution: Refrigerate at 2 to 8°C at all times. Do not freeze.
• Keep away from direct light and heat at all stages; all three compounds have some light sensitivity in solution.
• Do not shake the bottle; gently invert once or twice before use if any settling is observed.
• Use clean technique when administering; avoid touching the spray tip to any surface to prevent contamination.
• Do not transfer to a non-sterile container.

Where To Find Trusted Research Suppliers

For vetted suppliers trusted by this community, see our USP Trusted Vendors List

DISCLAIMER

The information in this guide is intended for educational purposes only and does not constitute medical advice.

This is the index. Every compound gets its own write-up. Every write-up links from here.

Most of what gets shared in this space is either incomplete, misapplied, or built on a game of telephone that started with one study abstract and ended up as gospel. Dosing protocols circulate without the pharmacokinetic reasoning behind them. Stacks get recommended without any explanation of why the mechanisms are complementary. That's the problem this library exists to fix.

The goal is straightforward: close the gap between what the research actually says and what's circulating in the community. Each post follows a consistent structure: mechanism first, data second, real-world context third. Compounds appear in more than one category when their mechanism warrants it.

Bookmark this. Share it when someone asks a question that deserves a real answer instead of a confidence-without-evidence reply. Comment below if it helped.

****This will be constantly edited and hyperlinks will be added****

Materials and Supplies

• Bacteriostatic Water - for reconstituting your peps
• Insulin Syringes (Amazon) - for injection
• Alcohol Swabs (Amazon) - cleaning your vials and injection sites
• Travel Ice Pack TSA Approved (Amazon) - keeping you peps cold while traveling
• Nasal Spay Bottles 10ml sterile - for making DIY Nasal spray solutions

Tools & Quick Links

• Peptide Dosage Calculator — plug in your vial size and BAC volume, get exact syringe units instantly
• Peptide Blends Reconstitution - cheat sheet for every peptide blend

🔥 Fat Loss and Metabolic Function

Peptides and compounds with verified or mechanistically plausible roles in energy expenditure, mitochondrial function, insulin sensitivity, or adipose tissue regulation.

Retatrutide: Triple agonist hitting GLP-1, GIP, and glucagon receptors simultaneously. The most effective weight loss compound currently in development, and the glucagon component is what separates it from everything else.

Tirzepatide: Dual GIP and GLP-1 receptor agonist with some of the strongest weight loss data in the library. The GIP component is specifically what separates its effect size from GLP-1 monotherapy.

Semaglutide: GLP-1 receptor agonist with the most robust clinical trial record in this library for weight loss and cardiovascular outcomes. The benchmark every newer multi-agonist is being measured against.

Cagrilintide: Long-acting amylin analog that increases satiety and slows gastric emptying. Primarily relevant as an adjunct to GLP-1 agonists, where the combination data becomes meaningful.

SLU-PP-332: ERR agonist driving mitochondrial biogenesis and fat oxidation. Early research, but the mechanism is legitimate and worth understanding.

BAM-15: Mitochondrial uncoupler that increases energy expenditure without raising body temperature. Not a peptide, but one of the more mechanistically interesting metabolic compounds currently being studied.

MOTS-c: Mitochondrial-derived peptide that activates AMPK and improves insulin sensitivity. Structurally distinct from a conventional peptide because it originates inside the cell.

SS-31 / Elamipretide: Targets cardiolipin on the inner mitochondrial membrane, improving ATP synthesis efficiency and reducing oxidative stress. One of the more mechanistically specific compounds in this category.

NAD+: Central redox cofactor with well-established metabolic biology. Not a peptide, but the science warrants inclusion regardless.

AOD-9604: C-terminal fragment of hGH isolated for fat oxidation without the IGF-1 and insulin resistance baggage of full-length GH. Effects are real but modest, and the marketing runs well ahead of the human data.

Tesamorelin: GHRH analog with actual clinical approval for visceral fat reduction. The human evidence here is more solid than most of what's in this library.

CJC-1295 No DAC: Produces short, physiologic GH pulses through GHRH receptor stimulation. The No DAC distinction matters: kinetics are fundamentally different from the DAC version.

HGH Fragment 176-191: Same isolated sequence as AOD-9604 under a different name. Enhances lipolysis without raising IGF-1, with real but narrow effects.

💪 Lean Muscle and Recovery: GH / IGF-1 Axis

Peptides that stimulate GH release, modulate IGF-1 activity, or promote tissue repair through anabolic signaling pathways.

Tesamorelin: The most robustly human-validated GHRH analog in this library for body composition. Clinical approval gives it a data floor most compounds in this section don't have.

CJC-1295 No DAC: Produces a natural GH pulse pattern and elevates IGF-1. The No DAC kinetics differ from the DAC version in ways that matter for protocol design.

CJC-1295 + Ipamorelin: GHRH and GHRP synergy that amplifies both GH pulse amplitude and frequency. The gold standard peptide stack for GH optimization and the most popular starting point in this community.

MK-677 / Ibutamoren: Oral ghrelin mimetic that sustains elevated GH and IGF-1 around the clock. Not a peptide, but the go-to for people who want GH benefits without injections.

Sermorelin: GHRH analog that stimulates endogenous GH production rather than replacing it. One of the more forgiving entry points into the GH axis.

Ipamorelin: Ghrelin mimetic that triggers selective GH release without the cortisol or prolactin elevation that comes with less selective GHRPs.

Hexarelin: Potent GHRP with strong GH release and additional cardiac receptor activity. More aggressive than Ipamorelin, with a higher side effect threshold to match.

IGF-1 LR3: Long-acting IGF-1 analog with no approved human indication. Performance claims in this community consistently exceed what the clinical literature supports.

PEG-MGF: Pegylated IGF-1 splice variant targeting satellite cell proliferation and localized muscle repair. No human clinical data, and pegylation meaningfully alters the pharmacodynamics vs. native MGF.

Follistatin-344: Myostatin inhibitor with coherent muscle growth biology. The limitation is that human bioactivity of the injectable form remains largely unvalidated.

🩹 Skin, Wound Healing, and Tissue Repair

Peptides with meaningful evidence for collagen remodeling, skin rejuvenation, or accelerated tissue repair.

GHK-Cu: Copper-binding tripeptide that stimulates collagen and elastin synthesis, with a stronger human and animal study base than most topicals. Delivery method affects bioavailability in ways worth understanding.

GLOW: GHK-Cu, BPC-157, and TB-500 in a single blend targeting collagen synthesis, angiogenesis, and tissue remodeling. The write-up covers how the three mechanisms interact and what the evidence supports for each.

KLOW: GLOW plus KPV, adding an NF-kB suppressing anti-inflammatory layer to the same repair stack. The write-up covers what the fourth compound actually changes about the protocol.

Melanotan 2: Multi-receptor melanocortin agonist that accelerates tanning through receptors that also drive libido effects. That's not a side effect: it's the mechanism.

BPC-157: Consistent angiogenesis and fibroblast migration signals in preclinical wound healing data. Human evidence is sparse, which is a real limitation worth knowing before diving into the full write-up.

TB-500 / Thymosin Beta-4: Facilitates keratinocyte and endothelial cell migration to promote wound closure and tissue remodeling. Preclinical support is solid; controlled human data doesn't exist yet.

KPV: Anti-inflammatory tripeptide that suppresses NF-kB and supports epithelial repair. The same mechanism applies to both skin and gut contexts.

LL-37: Enhances epithelial regeneration and repairs the skin barrier while simultaneously managing microbial burden and inflammation. The dual role is structural, not incidental.

SNAP-8: Topical neuromodulating peptide that reduces expression line depth by dampening neurotransmitter-driven muscle activity. The effect is real but more modest than cosmetic marketing implies.

RU-58841: Topical anti-androgen with a legitimate DHT-driven follicle miniaturization mechanism. Never approved, long-term safety uncharacterized, evidence is mostly early studies and community data.

🧠 Cognitive Function and Neuroprotection

Peptides with genuine mechanistic or evidentiary support for enhancing cognition, neuroplasticity, or protecting neural tissue.

Semax: Clinically used in Russia for BDNF upregulation and post-ischemic recovery. The evidence base is regional, not absent, and that distinction matters when evaluating the data.

Selank: Anxiolytic with cognitive support through GABA and serotonin modulation. Shares the same regional evidence structure as Semax and the same caveats.

Adamax: Modified Semax analog targeting BDNF and TrkB signaling with a more selective receptor profile. Novel compound with early but mechanistically coherent data.

Dihexa: Strong synaptogenic signals in rodent models via HGF/c-Met signaling. The mechanism is interesting; zero human trials exist and long-term safety is unknown.

SS-31 / Elamipretide: Mitochondria-targeted neuroprotection through the same cardiolipin mechanism as its metabolic applications. The dual-category listing reflects a genuinely dual mechanism.

VIP: Neuroprotective and anti-inflammatory signaling across circadian regulation and neurovascular function. Relevant across multiple tissue contexts through the same pathway.

🛡️ Immune Modulation and Inflammation Control

Peptides with well-supported roles in immune regulation, anti-inflammatory activity, or immune restoration.

Thymosin Alpha 1: Clinically validated T-cell and NK-cell modulator used therapeutically for immune deficiency and chronic infection. One of the most established compounds in this entire library.

VIP: Anti-inflammatory and immunoregulatory signaling across multiple tissue types through cytokine modulation and immune tolerance promotion.

KPV: Suppresses NF-kB and pro-inflammatory cytokines through a mechanism that covers both gut and skin immune applications simultaneously.

SS-31 / Elamipretide: Reduces mitochondrial ROS and oxidative inflammation through cardiolipin stabilization. The immune relevance follows directly from the mitochondrial mechanism.

LL-37: Regulates cytokine release, neutralizes bacterial toxins, and balances pro- and anti-inflammatory responses simultaneously. The dual role is structural.

⏳ Longevity and Cellular Protection

Peptides and cofactors with meaningful mechanistic or clinical evidence for impacting cellular aging, telomere dynamics, or mitochondrial integrity.

Epitalon: Pineal tetrapeptide with telomerase activation and circadian normalization data from Russian studies. Independent Western replication is limited, and that belongs in the confidence calculation.

SS-31 / Elamipretide: Reduces oxidative damage and improves ATP efficiency through mitochondrial cardiolipin binding, with human trial exposure across multiple indications.

MOTS-c: AMPK activation and metabolic stress-response support with a longevity signal mechanistically tied to mitochondrial energy status.

NAD+: Central redox cofactor for sirtuins and PARPs. The delivery debate is ongoing; the underlying biology is not.

Thymosin Alpha 1: Immune rejuvenation and cytokine balancing with established clinical use. Immune aging is an underrated driver of the broader longevity picture.

FOXO4-DRI: Induces apoptosis in senescent cells by disrupting the FOXO4/p53 complex. The most direct peptide-based approach to senolytics currently in preclinical research.

❤️ Sexual Function and Hormonal Regulation

Peptides with demonstrated or well-supported links to sexual health, libido, or hormonal axis modulation.

PT-141 / Bremelanotide: FDA-approved MC4R/MC3R agonist that drives libido and arousal through the CNS, not through hormonal changes. The centrally mediated mechanism is what separates it from hormone-based interventions.

Oxytocin: Neuropeptide that enhances bonding, trust, and sexual arousal via limbic system activity. Effects are CNS-driven and highly context-dependent.

Melanotan 2: Central MC4R activation for libido and arousal, sharing the same receptor mechanism as PT-141 with the addition of tanning from its broader receptor activity.

Kisspeptin-10: Activates GnRH neurons to drive LH, FSH, and downstream reproductive hormone release. As far upstream as peptide intervention into the hormonal axis currently goes.

How Each Write-Up Is Structured

Every post opens with a beginner-accessible overview: what the compound is, what it does mechanistically, and what the caveats are. From there: study design, pharmacokinetics, mechanism of action, preclinical and clinical outcomes, safety signals, regulatory context, and a community protocol summary for educational purposes.

The goal is the same across every write-up: give you the tools to evaluate the evidence yourself rather than hand you a verdict to memorize.

All content is for educational and research purposes only. Nothing in this library constitutes medical advice.

If you could rewind to day one, what’s the one thing you’d tell yourself?

Think about the one thing nobody told you that you had to figure out the hard way.

Could be dosing, sourcing, reconstitution, expectations, timing, whatever actually moved the needle.

What is it?

WHAT IS IT?

PT-141 / Oxytocin is a dual-compound nasal spray combining two of the most targeted compounds available for sexual desire, arousal, and intimacy enhancement into a single on-demand formulation. PT-141 activates the brain's desire and arousal circuitry through melanocortin receptor activation while oxytocin, often called the bonding hormone, deepens emotional connection, trust, and the relational quality of sexual experience simultaneously.

The combination addresses something no single compound can achieve alone: the full spectrum of sexual experience from neurological desire and physical arousal through to emotional intimacy and connection. Most sexual enhancement compounds target one dimension. This formulation targets all three at once.

WHO IS IT FOR?

Best suited for:

• Men and women who want the full PT-141 arousal and desire profile with the added emotional depth and connection that oxytocin provides
• Couples dealing with desire discrepancy, emotional disconnection, or reduced relational intimacy where both physiological and psychological dimensions need addressing simultaneously
• Individuals who find PT-141 alone produces strong physical arousal but want the emotional and bonding dimension amplified
• Those dealing with stress, emotional guardedness, or anxiety-driven intimacy barriers where oxytocin's trust and bonding effects directly address the root cause
• Women in particular, where the combination of desire restoration (PT-141) and enhanced emotional safety (oxytocin) addresses the two primary neurological drivers of female sexual responsiveness

Not ideal for:

• Individuals with uncontrolled hypertension or recent cardiovascular events given PT-141's transient blood pressure effects
• Those on antihypertensives without medical supervision
• Pregnancy or breastfeeding; oxytocin has uterotonic effects and is contraindicated in pregnancy
• People with active melanoma history or those who reacted poorly to MT-2
• Individuals who want purely physical enhancement without the emotional and relational dimension; the oxytocin component meaningfully shifts the experience toward connection and vulnerability

HOW IT WORKS

The two compounds operate through distinct but deeply complementary neurological pathways that together produce an experience qualitatively different from either alone:

Step 1: MC3 and MC4 receptor activation (PT-141) PT-141 binds melanocortin receptors in the hypothalamus, directly activating the neural circuitry underlying sexual desire and motivation. This triggers dopamine release in the mesolimbic reward pathway, producing proactive sexual drive rather than reactive arousal. The desire feels internally generated, which is the consistently reported qualitative distinction between PT-141 and every other sexual enhancement compound on the market.

Step 2: Dopaminergic reward activation (PT-141) Mesolimbic dopamine release produces anticipatory pleasure, motivation toward sexual activity, and the heightened engagement that users describe as the compound's most distinctive quality. This is the mechanism that makes sex feel wanted rather than simply possible.

Step 3: Oxytocin receptor activation in the brain and periphery Intranasal oxytocin crosses the blood-brain barrier via the olfactory pathway and binds oxytocin receptors in the amygdala, hippocampus, and hypothalamus. In the amygdala specifically, oxytocin reduces fear and threat-detection signaling, directly lowering the emotional guardedness and stress-driven disconnection that is one of the most common barriers to genuine intimacy, particularly in women.

Step 4: Trust, bonding, and social salience enhancement (Oxytocin) Oxytocin increases the perceived trustworthiness and attractiveness of a partner, enhances emotional attunement, and amplifies the subjective sense of connection during physical contact. Touch feels more meaningful. Eye contact feels more intimate. The emotional dimension of the experience is heightened in a way that purely physical arousal compounds do not produce.

Step 5: Peripheral vascular and physical response (PT-141) Downstream from hypothalamic MC4 activation, PT-141 drives neural pro-erectile signaling in men and increased genital blood flow and lubrication in women through central rather than vascular pathways. This peripheral physical response is additive to the emotional and desire effects rather than the primary mechanism, which is what makes this formulation fundamentally different from anything working purely on blood flow.

The combined effect PT-141 generates the neurological drive toward sex. Oxytocin removes the emotional barriers to it and deepens the quality of the connection during it. Together they address desire, arousal, and intimacy simultaneously in a way that mirrors and amplifies the full natural sexual response rather than isolating a single component of it.

DOSING

Standard dosing per administration:

• PT-141: 1 to 2mg intranasally
• Oxytocin: 20 to 40 IU intranasally
• Timing: 45 to 90 minutes before activity
• Frequency: As needed, maximum once per 24 hours
• Administration: One to two sprays per nostril depending on formulation concentration; wait 10 to 15 seconds between nostrils

Confirm the exact concentration of both compounds per spray with your supplier before calculating per-spray dosing. Formulations vary and accurate dosing requires knowing the specific volume per actuation.

First use protocol: Start at the lower end of both compounds on first use. PT-141's nausea risk is dose-dependent and oxytocin's emotional effects can feel unfamiliar or intense for first-time users, particularly those with significant stress or emotional guardedness in their baseline. Starting conservative allows both compounds to be assessed individually before moving to higher doses.

Common mistakes:

• Treating this as a purely physical enhancement tool; the oxytocin component shifts the experience meaningfully toward emotional openness and vulnerability, which requires the right context to be appreciated rather than felt as disorienting
• Dosing in a rushed, stressed, or distracted context; this combination is particularly sensitive to set and setting given oxytocin's social salience amplification
• Redosing within the same occasion; onset is slower than expected for first-time users and additional dosing increases side effect risk without improving the experience
• Heavy alcohol or large meals before dosing; both blunt absorption and worsen PT-141-related nausea

WHAT TO EXPECT

15 to 30 minutes Facial flushing and mild warmth signal PT-141 absorption. Oxytocin begins crossing into brain tissue via the olfactory pathway. Some users notice a subtle shift in social and emotional warmth toward their partner during this window, a gentle reduction in emotional guardedness that arrives before the more pronounced physical effects.

30 to 60 minutes Sexual desire begins building from the PT-141 dopaminergic component. Simultaneously, oxytocin's amygdala effects reduce anxiety and emotional defensiveness. Touch becomes more meaningful. Emotional attunement to a partner increases noticeably. This combination of rising physical desire alongside deepening emotional openness is the defining characteristic of this formulation versus PT-141 alone.

1 to 4 hours Peak effect window for both compounds. Physical arousal, desire, and emotional connection are all simultaneously active. Men report spontaneous arousal and strong erectile readiness alongside heightened emotional engagement. Women report enhanced sensitivity, lubrication, and a sense of emotional safety and openness that makes physical intimacy feel more natural and less effortful. Both partners typically report that sex feels more present, connected, and mutually engaged than baseline.

4 to 12 hours Gradual taper. The oxytocin component contributes to a notable post-experience warmth and relational closeness that persists well beyond the active window. Many couples report this as one of the most valuable aspects of the combination, a sustained improvement in relational warmth and communication quality in the hours and sometimes day following use.

STACKING

PDE5 inhibitors (Viagra, Cialis, Tadalafil) Adds peripheral vascular mechanics to PT-141's central neural pro-erectile signaling. Particularly valuable for men where vascular erectile dysfunction coexists with desire issues. Start both at lower doses when combining.

DSIP Sleep and HPA axis optimization builds the hormonal and neurological baseline that both PT-141 and oxytocin depend on for maximum response. Chronically poor sleep is one of the most common suppressors of both melanocortin receptor sensitivity and oxytocin system responsiveness.

Kisspeptin Emerging combination for comprehensive HPG axis and central desire optimization. Kisspeptin drives LH and downstream testosterone while PT-141 activates the central arousal pathway and oxytocin handles the bonding dimension. Limited human data but mechanistically one of the most complete sexual health stacks available.

Avoid combining with MT-2 simultaneously. Avoid other vasoactive compounds without medical oversight.

SIDE EFFECTS

Nausea (PT-141) The primary dose-limiting factor for this combination. Peaks at 30 to 90 minutes post-dose. Managed by starting at the lower dose, dosing on a light stomach, and avoiding alcohol. Typically diminishes with repeated use. If nausea is significant the dose is too high rather than the compound being poorly tolerated.

Facial flushing and warmth (PT-141) Universal at therapeutic doses, transient, and considered by most experienced users as a reliable indicator of active absorption rather than an adverse effect. Lasts 30 to 60 minutes.

Emotional intensity or vulnerability (Oxytocin) Oxytocin's reduction of amygdala threat-signaling can produce unexpected emotional openness, particularly in individuals who carry significant stress, past relational trauma, or emotional guardedness. This is generally experienced positively in the right context but can feel disorienting if the user is unprepared for it or using the compound alone. Worth being aware of rather than alarmed by.

Transient blood pressure increase (PT-141) Approximately 6 to 8mmHg systolic at standard doses, self-resolving within 12 hours. Clinically relevant for cardiovascular history or antihypertensive use.

Headache Reported by roughly 10 to 15% of users, typically mild and short-lived. Hydrate well before dosing.

Hyperpigmentation Residual MC1 activity from PT-141 can deepen existing moles and freckles with frequent ongoing use. Monitor with regular dermatological review for regular users.

Nasal irritation Mild and transient. Alternate nostrils and allow a few seconds between sprays for absorption before breathing in.

Priapism Rare but documented with PT-141. Any erection lasting more than 4 hours requires immediate medical attention.

STORAGE

Refrigerate at 2 to 8°C. Use within 30 days of preparation. Store away from light. Do not freeze. Do not shake. Store upright. Label with preparation date. Both compounds are sensitive to temperature cycling; avoid repeated removal from refrigeration between uses.

DISCLAIMER

For educational purposes only and does not constitute medical advice. 

Most healing peptides work locally. They drive repair at the site of injection or in the tissue immediately surrounding it.

TB-500 works systemically. It circulates, reaches damaged tissue throughout the body, and initiates repair from the inside out by solving the problem that sits upstream of most recovery failures: getting the right cells to the injury site in the first place.

The primary mechanism is actin regulation. Actin is the structural protein that governs cell shape, movement, and division. TB-500 sequesters actin monomers and controls their availability for filament assembly, which directly controls how fast and how efficiently cells can migrate. Keratinocytes to close skin wounds. Endothelial cells to form new blood vessels. Myoblasts to repair muscle fibers. Stem cells mobilized from bone marrow to damaged tissue. All of these require cell migration, and cell migration requires actin dynamics. TB-500 is the upstream regulator of that entire process.

This is why it differs from BPC-157 in a way that matters for stacking decisions. BPC-157 upregulates growth factor receptors and drives angiogenesis and repair signaling through VEGF and GH receptor pathways. TB-500 enables the physical movement of cells to the repair zone. One compound sets the blueprint, the other does the logistics.

One important distinction needs to be made clearly before going further: TB-500, as sold in research contexts, is typically the synthetic heptapeptide fragment corresponding to amino acids 17-23 of full-length Thymosin Beta-4 (Ac-LKKTETQ), not the complete 43-amino acid protein. The human clinical trial data from RegeneRx Biopharmaceuticals was conducted using full-length Thymosin Beta-4, not this fragment. Whether the injectable fragment behaves identically to the parent molecule in humans has not been rigorously tested in clinical trials. This distinction is glossed over in most posts on this compound and it belongs in any honest discussion of the evidence.

Let's go through it.

And before we begin, if you are wondering where to get it, you can get TB-500 from here.

What It Actually Is

Thymosin Beta-4 (Tβ4) is a naturally occurring 43-amino acid peptide encoded by the TMSB4X gene. It is one of the most abundant intracellular proteins in the human body, present in virtually all tissue types except red blood cells, with highest concentrations in platelets, white blood cells, plasma, and wound fluid. When injury occurs, Tβ4 is one of the first molecules released at the damage site, which is mechanistically significant: the body already uses it as a primary wound response signal.

TB-500, as it exists in research use, is a synthetic version of the active region of Tβ4, specifically the heptapeptide fragment Ac-LKKTETQ corresponding to amino acids 17-23. This fragment was identified in doping control research on equine samples and represents the actin-binding domain of the full-length molecule. It retains the cell migration and angiogenic activity associated with the full Tβ4 sequence but may not replicate the full biological profile of the 43-amino acid parent molecule.

The full Tβ4 molecule has distinct functional regions: amino acids 1-4 govern anti-inflammatory and anti-fibrotic effects, amino acids 1-15 inhibit apoptosis, and amino acids 17-23 (the TB-500 fragment) drive angiogenesis and cell migration. Running TB-500 means you are specifically targeting the migration and angiogenesis arm of what full Tβ4 does. This is still meaningfully active pharmacology, but it is not the complete picture of the parent molecule.

TB-500 is WADA prohibited at all times under S2. Validated doping control assays for the fragment exist. Competitive athletes subject to testing should treat this as a hard stop.

How It Works

Actin Sequestration and Cell Migration: The Core Mechanism

Actin exists in two forms inside cells: G-actin (globular, monomeric, unpolymerized) and F-actin (filamentous, polymerized). The dynamic interconversion between these two forms controls cell shape, movement, and division. TB-500 binds G-actin monomers and sequesters approximately 40-50% of the total G-actin pool in most cell types, maintaining a reserve of actin monomers available for rapid mobilization when migration signals arrive.

When a cell receives signals to migrate toward an injury site, TB-500 releases its sequestered actin to profilin, which catalyzes nucleotide exchange and directs actin monomers to growing filament ends at the leading edge of the cell. This allows the cell to extend membrane protrusions, move directionally, and travel through damaged tissue to the repair zone.

The practical implication: without adequate actin dynamics, repair cells stall. They are present in the body but cannot navigate efficiently to the injury site. TB-500 solves this bottleneck.

In wound healing studies, Tβ4 stimulated keratinocyte migration up to 300% over controls within five hours at concentrations as low as 10 picograms. This is potent cell migration activity at extremely small concentrations.

Angiogenesis

TB-500 promotes endothelial cell migration, tubule formation, and stabilization of new vascular structures through VEGF upregulation and direct effects on endothelial cell behavior. The LKKTET sequence specifically contributes to angiogenic activity. Mutations in this region substantially reduce the angiogenic capacity of the molecule.

New blood vessel formation is not optional for tissue repair. Damaged tissue with inadequate blood supply cannot receive the oxygen, nutrients, and repair signals needed for recovery. Chronic injuries, particularly in tendons and ligaments with already poor vascularity, benefit most from angiogenic support.

Anti-Inflammatory Activity

TB-500 reduces expression of pro-inflammatory cytokines including TNF-alpha and IL-1beta, helping to resolve the acute inflammatory phase of healing rather than allowing it to persist into chronic inflammation. It also activates the Akt/mTOR pathway, which promotes cell survival and reduces apoptosis in damaged tissue.

NF-kB modulation is part of this anti-inflammatory profile, though the mechanism is distinct from KPV's direct NF-kB nuclear translocation blockade. TB-500 approaches the inflammatory signaling cascade from a different entry point.

Stem Cell Mobilization

TB-500 recruits progenitor cells from bone marrow to sites of injury. This stem cell mobilization component is particularly relevant for severe or chronic injuries where local cell populations have been depleted or exhausted. It is also the mechanism behind the cardiac repair data: TB-500 activates dormant epicardial progenitor stem cells following myocardial infarction, contributing to cardiomyocyte regeneration and measurable improvements in cardiac ejection fraction in animal models.

Anti-Fibrotic Activity

By inhibiting TGF-beta-driven collagen deposition, TB-500 reduces fibrosis and scar formation in healing tissue. This is mechanistically important: unregulated fibrotic response to injury produces disorganized scar tissue rather than functional regenerated tissue. TB-500 shifts the balance toward organized repair. The Ac-SDKP tetrapeptide fragment of Tβ4 specifically carries anti-fibrotic properties and inhibits hematopoietic stem cell proliferation through a complementary mechanism.

What the Research Shows

Animal and Preclinical Data

Tβ4 accelerated wound healing in multiple rodent models including normal animals, diabetic mice (db/db), and aged mice where healing is typically impaired. In a full-thickness skin defect model, Tβ4 treatment sustained high expression of VEGF and basic fibroblast growth factor, improving the matrix environment for cell proliferation and migration throughout the healing timeline.

In burn wound models, Tβ4 improved wound closure through mechanisms associated with heat shock protein 70 expression and F-actin regulation.

Cardiac data: Tβ4 significantly reduced necrotic areas in cardiac ischemia models, increased VEGF expression and superoxide dismutase activity, and improved survival rates in animals receiving 5 mg/kg twice daily. This is the most compelling single-tissue data point in the TB-500 research profile and drove RegeneRx's decision to advance into human cardiac repair trials.

Neurological: Tβ4 treatment improved functional recovery in mouse models of experimental autoimmune encephalomyelitis, attributed to neurogenesis and axonal remodeling effects.

Hepatic: Tβ4 prevented oxidative stress, inflammation, and fibrosis in ethanol- and LPS-induced liver injury models in mice, suggesting protection against toxic hepatic insult.

Human Data: Full-Length Thymosin Beta-4 (Not TB-500 Fragment)

RegeneRx Biopharmaceuticals conducted Phase 1 and Phase 2 clinical trials using full-length Thymosin Beta-4. These are the only completed human trials relevant to this compound class.

Dermal ulcer Phase 2 trials showed statistically significant wound closure improvements in venous stasis ulcers compared to placebo. The full-length molecule was well tolerated with a clean safety profile.

Cardiac repair Phase 1/2 trials demonstrated safety and tolerability in injectable full-length Tβ4 for myocardial infarction applications. Phase 2 trials were paused due to funding constraints at RegeneRx rather than safety signals. The IND filings remain active.

Ophthalmology: Tβ4 eye drops have been evaluated for dry eye and corneal wound healing in human trials, demonstrating anti-inflammatory and wound healing activity at the ocular surface.

The critical caveat stated again: all human trial data is for full-length Thymosin Beta-4, not the TB-500 fragment. Whether the fragment produces equivalent systemic effects in humans at the doses used in research protocols has not been directly studied in controlled human trials. The mechanism is plausible and the preclinical data on the fragment is compelling, but the evidence gap is real.

What It Feels Like

TB-500 is a systemic compound and the effects reflect that. Unlike BPC-157, which produces fairly rapid localized responses, TB-500 operates on a longer timeline and its effects are more diffuse.

Week 1 to 2: Reduction in background inflammation and joint discomfort is the most consistently reported early effect. Chronic low-grade soreness in previously injured areas begins to quiet down. This anti-inflammatory effect precedes the structural repair timeline.

Week 2 to 4: Recovery between training sessions improves. Stalled or chronic injuries that have not responded to other interventions begin to show signs of progress. Range of motion in affected joints often improves as inflammatory load decreases and tissue begins remodeling.

Week 4 to 8: Structural changes in previously damaged tissue become more apparent. Tendon and ligament resilience under load improves. People running it alongside a training program report the ability to handle training stress that previously aggravated the injury site.

Systemic effects beyond the primary injury: skin quality and wound healing speed improve across the body, not just at the target injury site. This is consistent with TB-500's systemic mechanism of action rather than localized depot delivery.

The timeline for meaningful structural repair is longer than the timeline for inflammation reduction. Most people notice the anti-inflammatory effects in the first few weeks but need a full 8 to 12 week cycle to see real tissue-level improvement.

Dosing

Research use only. Not FDA-approved. WADA prohibited.

Route: subcutaneous injection. Intramuscular injection near the affected tissue is also used in some musculoskeletal protocols, though systemic subcutaneous administration is the more common approach given TB-500's systemic mechanism.

Standard research protocol:

Loading phase (weeks 1 to 4): 5 to 10 mg per week, typically split into two injections of 2.5 to 5 mg. Loading doses are used to build tissue levels and address acute or chronic injury backlog.

Maintenance phase (weeks 5 to 10): 2 to 5 mg per week, one to two injections. Maintains tissue levels for ongoing repair signaling without the higher loading dose.

Cycle length: 8 to 12 weeks total. Off-cycle break of 4 to 8 weeks before repeating.

Typical reconstitution: add 2.0 mL bacteriostatic water to a 5 mg vial, giving 2.5 mg/mL. On a U-100 insulin syringe, 1 unit delivers 25 mcg. A 2.5 mg dose equals 100 units (1.0 mL). Adjust syringe size accordingly for these larger volumes, a standard insulin syringe may not be practical for the loading phase doses.

Storage: lyophilized at -20°C. Reconstituted at 4°C.

Side Effects and Safety

The safety profile across RegeneRx's human trials with full-length Tβ4 was consistently clean. No serious adverse events were attributed to the compound across Phase 1 and Phase 2 trials.

Injection site reactions: mild redness, localized swelling, or discomfort at the injection site are the most commonly reported effects in research community protocols. These are typically mild and resolve within 24 to 48 hours.

Fatigue or tiredness has been reported by some users in the first week or two, possibly related to increased metabolic demand as systemic repair processes ramp up. Self-resolving.

Cancer: TB-500 promotes angiogenesis and cell migration, both of which are processes that tumors also exploit for growth and spread. This is the primary theoretical concern with the compound. No direct evidence establishes that TB-500 promotes tumor development in cancer-free individuals, but the mechanism warrants clear contraindication in anyone with active malignancy, suspected malignancy, or recent cancer history. This is not a minor caveat. It is the most significant safety consideration for this compound.

No hormonal disruption. No HPG axis suppression. No cortisol elevation. TB-500 is not an endocrine compound.

Long-term safety data in humans specifically for the TB-500 fragment does not exist in controlled trials.

TB-500 vs. BPC-157: Why Both Matter

This is the most common comparison question in the healing peptide space and it deserves a direct answer.

TB-500 and BPC-157 are not redundant. They target different rate-limiting steps in the same repair process.

BPC-157 upregulates growth hormone receptor expression in tendon fibroblasts, activates JAK-2/STAT signaling, drives angiogenesis through VEGFR2, and modulates nitric oxide pathways. It is primarily a growth factor signaling compound. It tells the tissue to repair itself and recruits vascular support through receptor-mediated signaling.

TB-500 solves the cell migration problem. It ensures the cells doing the repair can actually get to the site, move through damaged tissue efficiently, and form the new vasculature that makes sustained repair possible. It also provides systemic anti-inflammatory and anti-fibrotic coverage that BPC-157 does not specifically address.

Running both together means you are telling the tissue to repair (BPC-157) while simultaneously ensuring the cellular logistics needed to execute that repair are optimized (TB-500). The KLOW blend contains both for this reason.

There is no controlled human trial demonstrating additive or synergistic benefit from the combination. The rationale is mechanistic complementarity, which is a reasonable basis for stacking but is not the same as demonstrated combined efficacy.

Where To Find Trusted Research Suppliers

For vetted suppliers trusted by this community, see our USP Trusted Vendors List

Community

If you have run TB-500, post the actual data:

• What injury or condition were you targeting?
• Did you run a loading protocol or go straight to maintenance dosing?
• How long before you noticed meaningful improvement in the target area?
• Did you stack it with BPC-157 and if so did the combination feel different from either alone?

I have answered this question tons of times in the comments of one of my other posts, I thought it would be a good idea to give this question a full post to clear it up.

The three solutions and what they actually are

Sterile water is pure H₂O. Nothing added. Sterilized to eliminate microbial contamination, zero preservatives.

BAC water is sterile water with 0.9% benzyl alcohol added. That preservative inhibits bacterial growth over time, which is why it's the standard for multi-use vials.

Saline is sterile water with 0.9% sodium chloride added. Isotonic, meaning it matches the salt concentration of your body's fluids.

Nasal comfort ranked

Saline > Sterile water > BAC water

Saline barely registers. Sterile water stings slightly. BAC water burns a little because benzyl alcohol is an irritant at mucosal surfaces. All three work. Comfort is the tradeoff.

Shelf life after reconstitution

• BAC water: 28-30 days refrigerated (2-8°C). Standard for most peptides.
• Sterile water: 5-7 days. Single or fast-use vials usually. In a clinical setting, single time use.
• Saline: 7-14 days. The salt doesn't protect against bacterial growth the way benzyl alcohol does.

Some people run refrigerated saline-based nasal or peptide solutions 2–4 weeks, but that is usually informal practice, not the conservative sterility standard.

When saline may be chosen over BAC water, Saline may be preferred when:

• Compound is sensitive to benzyl alcohol
• User is allergic or sensitive to benzyl alcohol
• Intranasal or specialty formulations need isotonicity

****NOW WITH ALL THAT BEING SAID. This is me telling you my experience and not telling you what to do. I have personally used saline reconstituted solutions for injection and nasal for up to 30 days and everything was fine. I have used BAC water only reconstituted Reta that was 3 months old as well. I kept my vials clean, sterile, swabbed with alcohol before every injection. Im clean with it lol. As you should be as well. ****

Where to get your supplies

Sterile water - Search "sterile water for injection 10mL" - Comes in single use vials, cheap, widely available. Pick up a box and you're set for months.

BAC water - Search "bacteriostatic water 10mL" - Comes in multi-dose vials.

Saline - Search "sodium chloride 0.9% sterile saline 10mL" - Same deal as sterile water, single use vials, grab a box.

Nasal spray bottles - Search "10mL nasal spray bottle empty sterile"

What about mixing BAC water and saline?

Simple. Instead of reconstituting with sterile water, you use BAC water directly in the vial. Add 2 mL BAC water to your peptide powder, swirl gently until dissolved. Now draw out that full 2 mL reconstituted solution and inject it into a spray bottle that already has 2 mL saline sitting in it. Total volume is 4 mL. Done.

What you end up with is a solution that has the preservation of BAC water protecting the peptide, and the isotonic comfort of saline making up the other half of the bottle. Every spray delivers a solution that sits closer to what your nasal tissue actually wants to feel.

The tradeoff worth knowing: the benzyl alcohol concentration in the final bottle is roughly half of what it would be in a straight BAC water build, around 0.45% instead of 0.9%. Still works, benzyl alcohol is effective down to around 0.5%, but you're closer to the lower bound. Treat the window as 28 days and don't push it.

Best suited for daily-use peptides like Semax and Selank where you're spraying every day and comfort adds up. For on-demand compounds like PT-141 and MT-II where the bottle sits untouched for days at a time, reconstitute with BAC water and dilute with BAC water. You want full preservative strength when usage is unpredictable.

Building the spray bottle

Same process every time. 2 mL diluent into the bottle first, then 2 mL reconstituted peptide solution on top. Total volume always 4 mL. One spray delivers 0.1 mL.

Universal formula: total mg divided by total mL equals mg/mL. Multiply by 0.1 to get mg per spray. Works for any peptide, any volume.

Semax: 5 mg vial (125 mcg/spray)

Reconstitute with 2 mL BAC water, concentration becomes 2.5 mg/mL. Draw out solution, inject into spray bottle containing 2 mL saline. Final concentration 1.25 mg/mL.

Typical daily dose: 200-400 mcg, 2-4 sprays split between nostrils.

At 200 mcg/day (20 days of solution):

• Sterile water or saline only: exceeds the window, stability limits before the bottle is empty.
• BAC water only: covered at 28-30 days.
• BAC + saline: covered, smoother delivery, stay conservative on the window.

At 400 mcg/day (10 days of solution):

• Sterile water or saline only: past the safe window.
• BAC water or BAC + saline: covered comfortably.

Semax: 10 mg vial (250 mcg/spray)

Reconstitute with 2 mL BAC water, concentration becomes 5 mg/mL. Draw out solution, inject into spray bottle containing 2 mL saline. Final concentration 2.5 mg/mL.

At 200 mcg/day (40 days of solution):

• Sterile water or saline only: not appropriate.
• BAC water only: exceeds the window. Split into two builds or dose higher.
• BAC + saline: same, split the build.

At 400 mcg/day (20 days of solution):

• Sterile water or saline only: not appropriate.
• BAC water or BAC + saline: covered.

Selank: 5 mg vial (125 mcg/spray)

Reconstitute with 2 mL BAC water, concentration becomes 2.5 mg/mL. Draw out solution, inject into spray bottle containing 2 mL saline. Final concentration 1.25 mg/mL.

Typical daily dose: 250-750 mcg, 2-6 sprays per day.

At 250 mcg/day (20 days of solution):

• Sterile water or saline only: exceeds window.
• BAC water or BAC + saline: covered.

At 500 mcg/day (10 days of solution):

• Sterile water or saline only: borderline, high risk.
• BAC water or BAC + saline: covered.

At 750 mcg/day (7 days of solution):

• Sterile water or saline only: right at the edge, still risky.
• BAC water or BAC + saline: covered. At this dose frequency the comfort benefit of the saline split is most noticeable.

Selank: 10 mg vial (250 mcg/spray)

Reconstitute with 2 mL BAC water, concentration becomes 5 mg/mL. Draw out solution, inject into spray bottle containing 2 mL saline. Final concentration 2.5 mg/mL.

At 250 mcg/day (40 days of solution):

• Sterile water or saline only: not appropriate.
• BAC water or BAC + saline: exceeds window. Split the build.

At 500 mcg/day (20 days of solution):

• Sterile water or saline only: not appropriate.
• BAC water or BAC + saline: covered.

At 750 mcg/day (13 days of solution):

• Sterile water or saline only: exceeds window.
• BAC water or BAC + saline: covered.

PT-141: 10 mg vial (250 mcg/spray)

Reconstitute with 2 mL BAC water, concentration becomes 5 mg/mL. Draw out solution, inject into spray bottle containing 2 mL BAC water. Final concentration 2.5 mg/mL.

Dosing: 0.5-2 mg per use, 2-8 sprays. On demand, not daily.

Sterile water and saline are not realistic options here. Usage is irregular, the bottle sits between doses. Reconstitute with BAC water, dilute with BAC water. Full preservative strength only.

Build fresh every 28-30 days. At 2x per week you'll use roughly 8 doses per build, well matched to the window.

Hits faster nasally than subQ for most people. Start at 0.5 mg. Nausea is common and the nasal route amplifies it.

Melanotan II: 10 mg vial (250 mcg/spray)

Reconstitute with 2 mL BAC water, concentration becomes 5 mg/mL. Draw out solution, inject into spray bottle containing 2 mL BAC water. Final concentration 2.5 mg/mL.

Dosing: 500 mcg-1 mg per use, 2-4 sprays. On demand.

Same rule as PT-141. BAC water only, both reconstitution and dilution. On-demand compounds with irregular use need full preservative strength. Build fresh every 28-30 days.

Start conservative. Nausea and facial flushing are common, especially early. Dose in the evening until you know how you respond.

My Final Notes

Run the math before you build, not after. Total volume divided by daily usage tells you exactly how long the bottle needs to last. Match your diluent to that number.

Sterile water or saline only: fast-use builds finished within a 7-14 days. BAC water only: on-demand compounds, anything unpredictable. BAC water reconstitution into saline: daily peptides where you want full shelf life with better nasal comfort.